

# 17<sup>th</sup> WORLD DERMATOLOGY CONGRESS

September 25-26, 2017 Dubai, UAE

## The outcome of using topical Sirolimus in capillary malformations among patients in King Faisal Specialist Hospital: Case series

Hebah M Musalem<sup>1</sup>, Aljoharah A Alshaikh<sup>1</sup>, Lin M Tuleimat<sup>1</sup> and Saad M Alajlan<sup>2</sup>

<sup>1</sup>Alfaisal University, KSA

<sup>2</sup>King Faisal Specialist Hospital and Research Center, KSA

**Background:** Sirolimus, a mammalian target of Rapamycin (mTOR) inhibitor was approved by the FDA in 2015 for lymphangiomyomatosis (LAM). Recently, Sirolimus has been added to the treatment of vascular anomalies in King Faisal Specialist Hospital (KFSH), which raised interest to investigate its efficacy in capillary malformations, such as PWS. Since the market is lacking commercial topical preparations, pharmacists in KFSH were encouraged to formulate topical Sirolimus. PWS is a congenital, progressive capillary malformation of skin, occurs on the face, neck and body as a flat lesion. PDL is the current treatment of choice for PWS.

**Objective:** To reinforce the efficacy and safety of combining topical Sirolimus with pulsed dye laser (PDL) in managing capillary malformation, as port wine stain (PWS); aiming for better clinical clearance.

**Methods:** Review of retrospective documents for a total of 5 cases regarding port wine stain that were treated with Pulse Dye Laser (PDL) initially, followed by the addition of 0.5%-1% topical Sirolimus as a Dual Therapy (PDL and Topical Sirolimus).

**Results:** PDL therapy reflected insufficient improvement (0% up to 55%) and frustrating side effects following multiple sessions over many years. On the other hand, the Dual Therapy reflected significant clearance by an average of 20% in shorter duration and minimized the intolerable side effects of using PDL alone.

**Conclusion:** We propose implementation of topical Sirolimus in managing PWS and other capillary malformations. Furthermore, prospective studies should be conducted regarding safety and efficacy of using Dual Therapy for managing PWS..

### Biography

Hebah M Musalem is a Medical Intern, graduated from Alfaisal University, KSA. She is one of the Head Organizers of Alfaisal Dermatology Club and a Member of The Saudi Society of Dermatology and Dermatologic Surgery. She has studied Pharmacology and Pharmaceutical Science for 4-years. She was nominated to be the Head of Treasury Committee of the Medical Student Association for 2 years. She has also focused on clinical research and participated in writing multiple papers with great consultants from different department, especially dermatology department and has a research experience of a period of 3 years.

hebamusallam91@gmail.com

### Notes: